Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new‐generation drug‐eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)‐4 trial

BACKGROUND: About 5%–15% of acute coronary syndrome (ACS) patients undergoing stent implantation have concomitant atrial fibrillation and need both antiplatelet and anticoagulant therapies. The optimal antithrombotic regimen remains uncertain in this scenario. HYPOTHESIS: A multicenter randomized co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaoxuan, Hua, Rui, Bai, Jianling, Wu, Tianyu, Wang, Qin, Zhang, Jinhua, Zhang, Wenhao, Ying, Lianghong, Ke, Yongsheng, Wang, Xiaoyan, Zhang, Xiwen, Liu, Kun, Chen, Yan, Zhang, Boqing, Dong, Peng, Xiao, Jianqiang, Li, Changling, Zhu, Li, Li, Chunjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Clinical Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352971/
https://www.ncbi.nlm.nih.gov/pubmed/37191146
http://dx.doi.org/10.1002/clc.24025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352971/
https://www.ncbi.nlm.nih.gov/pubmed/37191146
http://dx.doi.org/10.1002/clc.24025

Ejemplares similares